Global Theranostics Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Disease (Neurological Disorders, Cardiovascular Diseases, Immunological Disorders, Oncology Others), Technology (Polymerase Chain Reaction (PCR), Immunohistochemistry, In Situ Hybridization, Sequencing, Others), End User & Region - Industry Forecast (2024 to 2029)

Updated On: January, 2024
ID: 5757
Pages: 175

Global Theranostics Market Size (2024 to 2029)

As per our report, the global theranostics market size is estimated to reach USD 196.30 Million by 2029 from USD 108.60 Million in 2024, to grow at a 12.2% CAGR from 2024 to 2029.

Theranostics is a new field of medicine combined with specific therapies based on specific diagnostic tests. Theranostics helps gather diagnostic and therapeutic applications to a single agent allowing for drug delivery, diagnosis, and treatment response monitoring which are majorly used to treat cancer. This treatment uses diagnostic imaging for the determination of the presence of target receptors on cancer cells, uses a combination of imaging and molecular radiotherapy, precise radiation therapy directed at receptors, determine the presence of a molecular target intending a specific drug, and uses positron emission tomography to identify the tumor.


Rising incidences of cancer and other chronic illness and growing investments in biological research are majorly propelling the global theranostics market growth.

The post-cancer treatments take time for the total recovery of the patients. The increasing need to treat cancers like kidney, brain, breast, and liver creates a massive opportunity for the players in the market. The growing R&D and the approvals for producing products from the FDA also expect the theranostics market growth. Another key driver boosting the global theranostics market monitored by the pharmaceutical sector is the reduced required time for medical trials.

The wide adoption of Theranos is due to its wide application in the diagnosis and treatment of the following diseases; neuroendocrine tumors, liver tumors, bone metastatic prostate cancer, metastatic prostate cancer, and thyroid cancer, as a result of its patient-centered focused care, making a transition from conventional medicine to personalized medicine. It is a personalized treatment plan, which has been emerging as a safe and effective targeted pharmacotherapy based on the uniqueness of each individual, leading to more effective medication provision for the right patient at the right time. Furthermore, being a cost-effective, practical, and specific treatment protocol, it plays an essential role in genetics, proteomics, pharmacogenetics, and biomarker profiling, which forms the backbone of theranostics, thereby driving the growth of the global theranostics market.

The rise in the prevalence of effective treatment procedures at any cost is solely to contribute to growth opportunities for the global theranostics market. Increasing incidences of chronic diseases are greatly influencing the demand of the market. Furthermore, growing investments in research institutes in the biotechnology field and awareness of manufacturing quality drugs with advanced Technology is likely to outshine the market's growth. People's interest in early diagnosis is also spurring the demand in the theranostics market.


The Shortage of skilled physicians due to the lack of training programs in healthcare institutes quietly hampers the demand of the global theranostics market. In addition, the cost of installing and maintaining the devices in the laboratories and stringent rules and regulations by the government for approval of new products are some factors challenging the market growth.

Impact of COVID-19 on the global theranostics market

In the making process of nanomachines that can carry the drug to the diseased cells without affecting the adjoining cells, nanoparticles are used. The process is called theranostics, a combination of therapies and diagnostics. COVID-19 has disrupted the healthcare sector in the name of supply chain and demand-side disruptions. Fortunately, in the case of Nanomedical science, theranostics helps mitigate the virulence effects in the infected persons. The virus is targeted with nuclear medicine that takes the principle of theranostics. As theranostics are usually applied in oncology and other tumor-related disorders, due to the outbreak, the demand for the theranostics market had become sluggish due to the fear induced in the people about hospital visits. But when the pandemic is subdued, and the virus becomes a lifestyle changer, medical experts have researched the virus's presence in the body and tried to inhibit the virus using Theranostics. Even in the US, the former presidents asked to check for theranostics treatment for COVID-19-infected patients. This has surged the demand for the expansion of nanoparticle medicine, especially theranostics for inhibiting the viral load in covid infected patients.

Also, the vaccine and drug-related treatment of COVID-19 may seem ineffective when the virus mutates, as the process only involves surface-related antigen tests. But to identify the correct viral load, the MRI technique can identify the virus's physical properties and the infected tissues for administering the targeted medicine or drugs.




Market Size Available

2023 to 2029

Base Year


Forecast Period

2024 to 2029

Segments Covered

By Disease Type, Technology, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Market Leader Profiled

Abbott Laboratories, AmeriPath, Dickinson and Company, BIOTEC Laboratories, Dade Behring, Dianon Systems, Dynacare Laboratories, Enterix, Focus Diagnostics, Pfizer, and Beckman Coulter.


Theranostics Market - By Disease Type

Based on Disease Type, Neurological disorders are the holding a significant share in the market due to the prevalence of diseases like Parkinson's Disease, Alzheimer's Disease, and other prevalent diseases; meanwhile, cancer diseases and cardiovascular disorders are expected to grow the fastest due to increased risk rate and prevalence of these diseases and increasing research expenditure by pharmaceutical companies. In addition, the emergence of the brain theranostics field, involving the visualization of brain disease through the designing of probes and monitoring levels of biomarkers in tissues, has improved diagnosis and treatment efficacy.

The cardiovascular diseases segment is estimated to grow at a high rate due to the rise in cardiovascular imaging, which can corroborate and extend pathophysiological evidence for cardiovascular disease. Furthermore, it is a valuable tool for atherosclerosis, providing the concept for medical treatment, the surrogating endpoint for clinical trials, and predicting the responsiveness.

Theranostic methods can also be applied in the treatment of cancers, leading to its dominance in the market. It is made for treating basal cell carcinoma, prostate cancer, esophageal cancer, breast cancer, actinic cheilitis, macular degeneration, actinic keratosis, and Bowen's disease.

Theranostics Market - By Technology

Based on Technology, Polymerase chain reaction technology accounts for holding the most significant shares of the market. For example, a specific DNA fragment can be amplified quickly in the lab using the polymerase chain reaction, producing millions to billions of copies that can then be further examined. In addition, increasing awareness of diagnostic and treatment procedures among individuals is fueling the growth of this market.

The method most frequently used nowadays for antibody theranostics for solid tumors is immunohistochemistry (IHC), which is expected to dominate the market. IHC can be used to employ the antibody to find the target expression in tumor tissue. The same antibody can subsequently be employed for therapy if the section is determined to express the target positively.

Theranostics Market – By End User

Based on End-User, the Hospital sector is ruling with dominant market shares. The growing scale of healthcare and diagnostics centers is a significant factor in boosting the market's growth. Also, increasing disposable income in urban areas is magnifying the growth of the Global Theranostics market.

Diagnostics Laboratories is anticipated to show a significant market share since theranostics is a proposed process of diagnostic therapy for the patients testing and tailoring treatment with a possibility for reaction to taking a new drug discovery.


Geographically, the North American theranostics market is estimated to hold a leading share in the global theranostics market during the forecast period due to market leaders and developed healthcare and pharmaceutical infrastructure. However, in North America, cancer-treated patients have less idea about post-cancer treatments and the high cost of these treatments is expected to be a challenge. Therefore, the prices of the therapies are high, and the experimental nature will still be the barrier to the growth in the theranostics market—the Shortage of skilled professionals due to lack of training hampering the demand for the treatments. In addition, the rigid regulations and rules made by the governments for the new production of products are challenging for the market.

The Asia Pacific theranostics market is the fastest-growing region due to increasing healthcare expenditure, product innovation, and rising disposable income. In Japan, the largest radiopharmaceutical company Nihon Medi-Physis (NMP), announced a package of JPY-3.3 billion for new research facility provisioning to theranostics. The NMP center promises to utilize an amalgamation of therapy mechanisms using ordinary molecules using peptides or antibodies. As a result, the center promises to deliver advanced drugs to cancer patients. These factors further help the global market for theranostics increase over the forecast period.


Companies leading the global theranostics market profiled in this report are Abbott Laboratories, AmeriPath, Dickinson and Company, BIOTEC Laboratories, Dade Behring, Dianon Systems, Dynacare Laboratories, Enterix, Focus Diagnostics, Pfizer, and Beckman Coulter.


  • In November 2022, committed fundamental tools and technologies creating company MGI launched a new Customer Experience Center (CEC) in Berlin, located at the facilities of ALACRiS Theranostics GmbH, for its support for clinical and research purposes with unique clinical precision oncology solutions, facilitating an individualized approach to cancer treatment to increase value for its customers and local partners.
  • In October 2022, Radiopharm Theranostics, a developer of a world-class platform of radiopharmaceuticals for diagnostic and therapeutic use, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development of radiopharmaceuticals, entered into a clinical supply agreement for the supplement of actinium-225 to be used in drug trials involving targeted alpha therapy.
  • In October 2022, an Australia-based clinical-stage radiopharmaceutical company, Clarity Pharmaceuticals, successfully treated its first patient in Phase I/II theranostic trial with metastases resistant to castration using SAR-bisPSMA, a cost-effective, next-generation platform for the treatment of patients with prostate cancer.
  • In October 2022, EANM showcased developments in Telix's theranostics portfolio regarding advances in imaging, surgery, and patient management in genitourinary oncology.


This research report on the global theranostics market is segmented and sub-segmented based on the disease type, Technology, end-user, and region.

By Disease Type

  • Neurological Disorders
  • Cardiovascular Diseases
  • Immunological Disorders
  • Oncology
  • Others

By Technology

  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry
  • In Situ Hybridization
  • Sequencing
  • Others

By End User

  • Hospitals
  • Diagnostics Laboratories
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Please wait. . . . Your request is being processed

Frequently Asked Questions

How much is the theranostics market going to be worth by 2028?

The global theranostics market is estimated to reach 171.91 billion by 2028.

who are the key players of the global theranostics market?

AmeriPath, Dickinson and Company, BIOTEC Laboratories, Dade Behring, Dianon Systems, and Dynacare Laboratories are some of the key market players in the theranostics market.

which region accounted for the largest share in the global theranostics market?

The global theranostics market in North America is expected to grow significantly and hold the largest share of the revenue during the forecast period.

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1800

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample